Donald J. Johann profile photo

Donald J. Johann

Federal Grant PI High Impact

Professor

Last publication 2025 Last refreshed 2026-05-22

faculty

Biomedical Informatics, College of Medicine

23 h-index 117 pubs 2,475 cited

Biography and Research Information

OverviewAI-generated summary

Donald J. Johann's research focuses on the application of high-throughput sequencing and mass spectrometry techniques for the detection of cancer biomarkers, particularly circulating tumor DNA (ctDNA).

His work investigates the analytical validity and performance of next-generation sequencing (NGS) assays used in precision oncology. This includes developing and verifying genomic reference samples to assess the accuracy of cancer panels in detecting low-frequency genetic variants. Johann has published studies evaluating the sensitivity and accuracy of various oncopanels, noting that performance can depend on specific genomic regions and sample processing methods, such as the degradation of quality in formalin-fixed paraffin-embedded (FFPE) samples based on their position within the block.

He also contributes to the development of data commons for liquid biopsy research, such as the BloodPAC Data Commons. His research has received federal funding, including a $750,000 grant from the NIH/National Institute of General Medical Sciences for an advanced next-generation sequencer. Johann leads a research group and collaborates with researchers at the University of Arkansas for Medical Sciences and the National Center for Toxicological Research.

Metrics

  • h-index: 23
  • Publications: 117
  • Citations: 2,475

Selected Publications

  • Generic Protocols for Analytical Validation of Tumor-Informed Circulating Tumor DNA Assays for Molecular Residual Disease: The Blood Profiling Atlas in Cancer's Molecular Residual Disease Analytical Validation Working Group Consensus Recommendation (2026)
    2 citations DOI OpenAlex
  • Lexicon for Clonal Hematopoiesis in Liquid Biopsy (2025)
  • Harnessing Native-Resolution 2D Embeddings for Lung Cancer Classification: A Feasibility Study with the RAD-DINO Self-supervised Foundation Model (2025)
  • EET-Based Therapeutics Mitigate Sorafenib-Associated Glomerular Cell Damage (2025)
  • Augmenting precision medicine via targeted RNA-Seq detection of expressed mutations (2025)
    4 citations DOI OpenAlex
  • Recommended Clinical Context and Patient Context Data Elements for Liquid Biopsy Data Submitted to Data Repositories and Data Commons (2025)
    1 citation DOI OpenAlex
  • Towards Preanalytical Best Practices for Liquid Biopsy Studies: A BLOODPAC Landscape Analysis (2024)
    7 citations DOI OpenAlex
  • Targeted DNA-seq and RNA-seq of Reference Samples with Short-read and Long-read Sequencing (2024)
    7 citations DOI OpenAlex
  • A Microdissection Protocol for Proteogenomic Analysis of Histological Sections to Advance Drug Development (2024)
  • Advancing drug development by leveraging microdissection for proteogenomic analysis of histological sections. (2024)
  • Abstract PO5-02-05: Assessing Vaccine-Mediated Cellular Immune Responses in Patients Receiving Combined Vaccine and Chemotherapy Treatment (2024)
  • Assessments of tumor mutational burden estimation by targeted panel sequencing: A comprehensive simulation analysis (2023)
    1 citation DOI OpenAlex
  • Liquid biopsy based on circulating tumor DNA for lung cancer: A step toward prevention (2023)
  • Contrived Materials and a Data Set for the Evaluation of Liquid Biopsy Tests (2023)
    12 citations DOI OpenAlex
  • An advanced molecular medicine case report of a rare human tumor using genomics, pathomics, and radiomics (2023)
    5 citations DOI OpenAlex

View all publications on OpenAlex →

Federal Grants 1 $750,000 total

NIH/National Institute of General Medical Sciences Contact PI Jun 2024 - Jun 2025

NovaSeq X Plus, Advanced Next Generation Sequencer

National Institute of General Medical Sciences $750,000 S10

Grants & Funding

  • Scientific and methodological advancement in liquid biopsies to further the development of lung cancer-based precision medicine (Bio 3) U.S. Food and Drug Administration - Pass Through: Arkansas Research Alliance Principal Investigator
  • Development and Validation of a Microdissection Method to Advance Precision Medicine in the Clinical Setting - Continuation - Continuation NIH/Nat. Cancer Institute Principal Investigator
  • Financial Support for the Breast Cancer Intergroup Correlative Science Studies Breast Cancer Research Foundation - Pass Through: University of Michigan Principal Investigator
  • NovaSeq X Plus, Advanced Next Generation Sequencer NIH/Office of the Director Principal Investigator
  • NovaSeq X Plus, Advanced Next Generation Sequencer NIH/Office of the Director Principal Investigator
  • Center for Studies of Host Response to Cancer Therapy NIH Co-Investigator
  • Scientific and methodological advancement in liquid biopsies to further the development of lung cancer-based precision medicine U.S. Food and Drug Administration - Pass Through: Arkansas Research Alliance Principal Investigator
  • Scientific and methodological advancement in liquid biopsies to further the development of lung cancer-based precision medicine U.S. Food and Drug Administration - Pass Through: Arkansas Research Alliance Principal Investigator

Collaboration Network

292 Collaborators 122 Institutions 15 Countries

Top Collaborators

View profile →
View profile →

Similar Researchers

Based on overlapping research topics